Background/Aims: Helicobacter pylori infection induces aberrant DNA methylation in gastric mucosa. We evaluated the long-term effect of H. pylori eradication on promotor CpG island hypermethylation in gastric carcinogenesis. Methods: H. pylori-positive patients with gastric adenoma or early gastric cancer who underwent endoscopic resection were enrolled. According to H. pylori eradication after endoscopic resection, the participants were randomly assigned to H. pylori eradication or non-eradication group. H. pylori-negative gastric mucosa from normal participants provided the normal control. CpG island hypermethylation of tumor-related genes (p16, CDH1, and RUNX-3) was evaluated by quantitative MethyLight assay in non-tumorous gastric mucosa. The gene methylation rate and median values of hypermethylation were compared after one year by H. pylori status. Results: In H. pylori-positive patients, hypermethylation of p16 was found in 80.6%, of CDH1 in 80.6%, and of RUNX-3 in 48.4%. This is significantly higher than normal control (p16, 10%; CDH1, 44%; RUNX-3, 16%) (p<0.05). In the H. pylori eradication group, methylation rates of p16 and CDH1 decreased in 58.1% and 61.3% of the patients, and the median values of hypermethylation were significantly lower at one year compared with the non-eradication group. However, RUNX-3 hypermethylation did not differ significantly at one year after H. pylori eradication. The non-eradication group hypermethylation did not change after one year. Conclusions: H. pylori infection was associated with promotor hypermethylation of genes in gastric carcinogenesis, and H. pylori eradication might reverse p16 and CDH1 hypermethylation. (Korean J Gastroenterol 2016;68:253-259) 
INTRODUCTION
Helicobacter pylori infection is one of the most prevalent infectious diseases worldwide and 40-50% of the global human population is estimated to be infected. H. pylori has been identified as group I carcinogen by the World Health Organization International Agency for Research on Cancer and is associated with the development of gastric cancer. 
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The Korean Journal of Gastroenterology Aberrant DNA methylation is one of the most frequent epigenetic changes, usually at the 5'position of the cytosine ring within CpG dinucleotides, and its influence is gene silencing and noncoding genomic regions. 2 Promotor CpG island hypermethylation is a crucial mechanism to silence tumor suppressor genes. 3 Aberrant CpG island hypermethylation occurs early in the multi-stage carcinogenesis. Gastric cancer is linked to tumor suppressor-related genes that are inactivated with by CpG island hypermethylation. 4 CpG island hypermethylation has been found in the adjacent noncancerous tissues of gastric cancer patients as well as normal gastric mucosa. 5 H. pylori infection induces aberrant DNA methylation in gastric mucosa, which raises gastric cancer risk. 6 Aberrant DNA methylation could be suppressed by H. pylori eradication. 7 However, whether suppression of aberrant DNA methylation lasts over the long term is unknown. We evaluated long-term effect of H. pylori eradication on promotor CpG island hypermethylation in gastric carcinogenesis.
In this study, we postulated that H. pylori infection might cause aberrant DNA hypermethylation of three gastric cancer-related genes (p16, CDH1, and runt-related transcription factor 3 [RUNX-3]), which are all tumor suppressor genes. [7] [8] [9] Eradication of H. pylori might reverse methylation of these genes over the long term. We investigated methylation of the p16, CDH1, and RUNX-3 genes in gastric mucosa from patients with gastric adenoma or early gastric cancer (EGC) before and after eradication of H. pylori after one year.
SUBJECTS AND METHODS

Patients and study design
In this study, gastric tissues were obtained from samples that were collected for another study. 10 according to the manufacturer's protocol.
MethyLight assay
The methylation assay of the p16, CDH1, and RUNX-3 genes from bisulfite modified DNA samples was performed with real-time PCR-based quantitative MethyLight technology. [13] [14] [15] Primers and probe for sequencing have been described. 16 Two sets of primers and probes designed to bond to bisulfite-con- 
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RESULTS
Subject characteristics
Eighty-three patients were enrolled in the study: 31 patients in H. pylori eradication group, 34 patients in non-eradication group, or 18 patients in normal control. There were no significant differences in baseline clinicopathological variables among the groups ( Table 2 ).
There was no statistical difference in hypermethylation rates between baseline and one year after eradication. We also analyzed quantitative methylation value of individual genes, which was possible owing to MethyLight assay. We found that median methylation value (PMR) of p16 and CDH1 was significantly lower at one year after eradication. For the p16 gene, median baseline PMR decreased significantly from 11.7 to 5.7 (p=0.004). For CDH1, median PMR decreased significantly from 47.9 to 7.0 (p=0.001). Conversely, RUNX-3
did not show any difference in methylation value (Fig. 1 ).
In the non-eradication group, rates of methylated the three genes were CDH1, 71.1%; PMR, 97.4%; and RUNX-3, 55.3%.
There were no significant changes in both hypermethylation rate and median methylation value at one-year follow-up.
Baseline p16, CDH1, and RUNX-3 genes had significantly higher methylation levels in H. pylori positive patients than in H. pylori-negative normal control (10%, 44%, 16%, respectively; p＜0.05) ( Table 2) .
We observed significant decrease in both neutrophilic and mononuclear inflammation in the gastric mucosa one year after H. pylori eradication (p=0.01). Conversely, there was no Fig. 1 . Changes in quantitative value of MethyLight assay (percentage of methylated reference, PMR) of p16, RUNX-3 and CDH1 at baseline and after one year in the Helicobacter pylori eradication group. PMR value in p16 and CDH1 were significantly reduced one year after eradication. change of the inflammation in the non-eradication group (data not shown). We tried to explain why some of eradicated patients still showed CDH1 and/or p16 hypermethylation even after the eradication. We compared patients who showed decreased methylation level of CDH1/p16 after the eradication with those did not in terms of initial H. pylori density, initial neutrophilic/mononuclear inflammation activity, or inflammation activity one year after eradication. We found no significant difference of inflammation activity or H. pylori density between groups.
We also analyzed methylation rates and median methylation level according to gastric adenoma or EGC type. In the eradication group, significant change in median methylation level of p16 was predominant in the EGC (PMR, 15. (Table 3) . We evaluated median methylation level of p16 in the EGC patients by differentiation type (well, moderately, poorly differentiated adenocarcinoma, or signet ring cell carcinoma). Initial methylation level of p16 was not different between well/moderately differentiated EGC and poorly differentiated/signet ring cell EGC. However, only well or moderately differentiated EGC decreased significantly in the methylation level of p16 after eradication (p=0.01). In terms of CDH1, significant change in PMR was found in EGC as well as adenoma. However, in the non-eradication group, there was no significant difference in methylation rate according to gastric adenoma or EGC.
DISCUSSION
In this study, the methylation levels in three genes (p16, CDH1, and RUNX-3) were evaluated from non-neoplastic gastric mucosae using quantitative real-time PCR, MethyLight assay. Baseline p16, CDH1, and RUNX-3 genes showed significantly higher methylation levels in H. pylori-positive patients than in H. pylori-negative normal control group. Some articles reported that patients with H. pylori had hypermethylation of p16 and CDH1 in 46-80%, while normal participants without H. pylori had no/little hypermethylation, 8, 18 which was in line with our study. However, we should consider that not all patients with H. pylori infection had hypermethylation of p16 and CDH1 although hypermethylation of these genes are associated with H. pylori infection. Rates of hypermethylation were variable, ranging from 30% to 82%. 8, 19 In addition, some studies reported that methylation of MLH1 and MGMT did not decrease significantly after H. pylori eradication. 8, 20 Conversely, a recent study showed that MGMT methylation was significantly reduced after H. pylori eradication in patients with H. pylori gastritis (from 70% to 48%). 21 These contradictory results suggest that the exact mechanism needs to be described, although researchers found epigenetic alteration associated with H. pylori in gastric carcinogenesis.
MethyLight is a sodium-bisulfite-dependent, quantitative, real-time PCR method to sensitively detect and quantify DNA methylation in genomic DNA. Methylation specific polymerase chain reaction (MSP) after sodium bisulfite conversion is used to determine DNA methylation status. However, due to its qualitative nature of assay, MSP cannot distinguish level of methylation. 15 The high sensitivity and specificity of However, not all patients experienced reduction of hypermethylation of relevant genes by H. pylori eradication.
8,18
Approximately 22-76% of patients who underwent eradication still had hypermethylation of the CDH1 gene and 18%
of patients still had p16 hypermethylation. 8, 18 Hypermethylation of RUNX-3 increased one year after H.
pylori eradication in this study, which suggests RUNX-3 may not be crucial in gastric carcinogenesis. However, some methylation profiles induced by H. pylori infection can persist even after eradication. 12 Several studies suggested RUNX-3 methylation as a risk factor for the gastric carcinogenesis in patients with H. pylori infection. 23, 24 One study suggested that epigenetic events and gene methylation were not evenly distributed throughout the gastric mucosa, so multiple biopsies in different parts of stomach should be performed to determine methylation status. 8 In this study, one biopsy was used for methylation status, which might be a limitation. Another limitation was the small number of participants.
In conclusion, H. pylori infection is associated with promotor methylation of genes in gastric carcinogenesis. H. pylori eradication might reverse CDH1 and p16 methylation levels.
Further studies are warranted to determine long-term effect of H. pylori eradication on DNA methylation.
